More on WellPoint (WLP -12.3%) Q2: Shares get battered following the Q2 miss and after it cuts its FY EPS outlook, citing higher medical costs and lower enrollment. Now expects $7.30-$7.40 vs. previous estimate of $7.57, which it backed a couple of weeks ago. Consensus is for $7.76. Projects year-end enrollment at 33.4M, -200K from previous estimate. Q2 net profit -8.3% to $643.6M, enrollment -1.9% to 33.5M.